**Lynne Warner Stevenson, MD, FACC**
**Director of Cardiomyopathy**
Vanderbilt University Medical Center

**Printed as of 11/18/2026**

# Disclosures

## Personal Commercial (7)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|---|---|
| ***Self*** | | | |
| Cytokinetics | Other - *unpaid consultation* | None ($0) | *Heart Failure and Cardiomyopathies* |
| Endotronix Inc/ Edwards LifeSciences | Research/Research Grants | None ($0) | *Heart Failure and Cardiomyopathies* |
| ***Spouse/Domestic Partner/Immediate Household Member*** | | | |
| Abbott Medical | Other - *honoraria for EP fellowship education course* | Modest (< $5,000) | *Arrhythmias and Clinical EP* |
| Biotronik | Other - *honoraria EP fellowship education* | Modest (< $5,000) | *Arrhythmias and Clinical EP* |
| Boston Scientific | Other - *honoraria for EP fellowship course* | Modest (< $5,000) | *Arrhythmias and Clinical EP* |
| Johnson and Johnson | Other - *Honoraria EP fellowship course* | Modest (< $5,000) | *Arrhythmias and Clinical EP* |
| Novartis- EP | Consultant Fees/Honoraria | Modest (< $5,000) | *Arrhythmias and Clinical EP* |

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (2)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|---|---|
| ***Self*** | | | |
| NHLBI | Other - *grant review* | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| NHLBI | Research/Research Grants | Significant (>= $5,000) | *Heart Failure and Cardiomyopathies* |

## Clinical Trial Enroller (1)

| Trial Name | Trial Sponsor | Trial Funding Source |
|---|---|---|
| ProACTIVE-II | Endotronix Inc/Edwards | |

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

*† Commercial Funding Source | ‡ Trial Name*

# Agreement

**Certified Education Attestation** | Signed on 12/19/2025
*URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 12/19/2025
*URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement*

**Embargo** | Signed on 12/19/2025
*URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement*

**On-Going Obligation Agreement** | Signed on 12/19/2025

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.